Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACTINIUM PHARMACEUTICALS, INC.

(ATNM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

07/30/2021 | 05:01pm EDT

Actinium Pharmaceuticals, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 266,000. Operating loss was USD 5.075 million compared to USD 4.662 million a year ago. Net loss was USD 5.021 million compared to USD 4.625 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.41 a year ago. For the half year, total revenue was USD 888,000. Operating loss was USD 10.447 million compared to USD 10.345 million a year ago. Net loss was USD 10.341 million compared to USD 10.295 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 1.2 a year ago.


ę S&P Capital IQ 2021
All news about ACTINIUM PHARMACEUTICALS, INC.
10/04ACTINIUM PHARMACEUTICALS : Announces Two Abstracts Highlighting Combinations of CD47 Targe..
AQ
09/29ACTINIUM PHARMACEUTICALS : to Present at the Cantor Fitzgerald Virtual Global Healthcare C..
AQ
09/29ACTINIUM PHARMACEUTICALS RALLY TAKES : Atnm)
AQ
09/28ACTINIUM PHARMACEUTICALS : Announces Expansion of R&D Team and Facilities to Accelerate Re..
AQ
09/28GENPREX : Appoints Mark Berger Chief Medical Officer
MT
09/23ACTINIUM PHARMACEUTICALS : Announces Multiple Senior Leadership Appointments Including Chi..
PU
09/23ACTINIUM PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regulation FD ..
AQ
09/23Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and..
CI
09/23ACTINIUM PHARMACEUTICALS RALLY INTAC : Atnm)
AQ
09/21ACTINIUM PHARMACEUTICALS STOCK JUMPS : Atnm)
AQ
More news
Analyst Recommendations on ACTINIUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 1,02 M - -
Net income 2021 -22,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,44x
Yield 2021 -
Capitalization 172 M 172 M -
Capi. / Sales 2021 169x
Capi. / Sales 2022 11,2x
Nbr of Employees 32
Free-Float 98,5%
Chart ACTINIUM PHARMACEUTICALS, INC.
Duration : Period :
Actinium Pharmaceuticals, Inc. Technical Analysis Chart | ATNM | US00507W2061 | MarketScreener
Technical analysis trends ACTINIUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 8,04 $
Average target price 30,00 $
Spread / Average Target 273%
EPS Revisions
Managers and Directors
Sandesh Seth Chairman & Chief Executive Officer
Steve O'Loughlin Chief Financial Officer
Dale L. Ludwig Chief Scientific & Technology Officer
Avinash Desai Chief Medical Officer
Mary Mei Chen Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ACTINIUM PHARMACEUTICALS, INC.8.85%175
GILEAD SCIENCES, INC.16.98%85 447
WUXI APPTEC CO., LTD.29.45%65 650
BIONTECH SE207.08%60 460
REGENERON PHARMACEUTICALS15.01%57 767
VERTEX PHARMACEUTICALS-23.03%47 190